A new approach that uses blood samples to identify cancer-specific proteins could address a major barrier in personalized cancer immunotherapy, according to a report by BioMedWire. Immunotherapy, a form of personalized cancer treatment, currently requires a tumor sample to be removed surgically and analyzed so that the personalized treatment needed by the patient can be manufactured.
However, obtaining the needed tumor sample can be challenging in many patients, such as those with tumors in hard-to-access parts of the body or those whose physical condition makes it risky to have surgery done to extract a sample. This limitation excludes some patients from potentially life-saving therapies and delays treatment initiation for others.
The blood-based approach, if validated, could allow clinicians to identify cancer neoantigens and specific T-cell activation without an invasive procedure. If additional clinical trials confirm the efficacy of the blood-based approach to obtaining data on cancer neoantigens and specific T-cell activation, the method could potentially reduce the time that is required to manufacture immunotherapies developed by entities like Calidi Biotherapeutics Inc. (NYSE American: CLDI) and others. Faster manufacturing could mean patients receive treatment sooner, which is critical for those with aggressive cancers.
The implications extend beyond convenience. A blood-based method could make immunotherapy accessible to patients who currently cannot undergo surgery, thereby expanding the eligible patient population. It could also enable more frequent monitoring of tumor evolution and treatment response, as blood draws are less invasive and can be repeated more easily than surgical biopsies. This could lead to more dynamic and adaptive treatment strategies.
Nevertheless, the approach requires further clinical validation. The report notes that additional trials are needed to confirm its efficacy. If those trials succeed, the method could fundamentally change how personalized immunotherapies are developed and delivered. For now, the research highlights a promising direction that could overcome a significant hurdle in cancer care.
BioMedWire is a specialized communications platform focused on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also provides article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public.
